Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

BACKGROUND: The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts be...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Cancer
Auteurs principaux: Irlam-Jones, J J, Eustace, A, Denley, H, Choudhury, A, Harris, A L, Hoskin, P J, West, C M L
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2016
Sujets:
Molecular Diagnostics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997544/
https://ncbi.nlm.nih.gov/pubmed/27441495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.218
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires